Working…
COVID-19 is an emerging, rapidly evolving situation.
Get the latest public health information from CDC: https://www.coronavirus.gov.

Get the latest research information from NIH: https://www.nih.gov/coronavirus.
ClinicalTrials.gov
ClinicalTrials.gov Menu

Yoga for Chronic Chikungunya (YOCHIK)

The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Read our disclaimer for details.
 
ClinicalTrials.gov Identifier: NCT04455919
Recruitment Status : Terminated (covid health crisis)
First Posted : July 2, 2020
Last Update Posted : July 2, 2020
Sponsor:
Information provided by (Responsible Party):
Centre Hospitalier Universitaire de Pointe-a-Pitre

Brief Summary:

The purpose of this study is to assess the benefits of a 8-week yoga program on quality of life in patients suffering from chronic chikungunya.

Studies have already shown the effectiveness of yoga practice on various arthralgia's, on the reduction of inflammatory reactions, on psychological disorders/sleep disorders and on quality of life. Considering quality of life as a global experience of balance between physical and mental wellbeing, the hypothesis was that the practice of yoga would globally improve the quality of life of patients with chronic chikungunya.


Condition or disease Intervention/treatment Phase
Chikungunya Virus Infection Other: Wait-list group Other: Yoga group Not Applicable

Detailed Description:

The chikungunya virus (CHIKV) is an arbovirus passed to humans by Aedes mosquitoes. Since its description in 1952, CHIKV has caused millions of human infections in Africa, the Indian Ocean islands, Asia, Europe and America (1). In total, since 2013, the epidemic has affected more than 2 million people in the Americas. In Guadeloupe, the emergence of chikungunya cases began in 2013. CHINKV was declared an epidemic in 2014 with an estimated 20,000 infected patients.Human infection with CHIKV is characterized by a sudden onset of severe joint pains, high fever and rash. The infection is self-limited and acute symptoms usually disappear within one or two weeks. However, this polyarthralgia is recurrent in 30 to 40% of infected people and can persist for years. Chikungunya is considered chronic if the symptoms persist after three months. The chronic stage can last from a few months to several years. Chronic chikungunya usually manifests as joint pain and stiffness, polyarthralgia (including rheumatoid arthritis, flare-ups of spondylitis), and other general symptoms such as intermittent headaches, edema, and paresthesia. The consequences of chronic CHIKV can be severe, with patients becoming maladjusted to their lifestyle, feeling weakened and diminished. Depression and medical leaves are very frequent, with many cases of disability. Yoga is an ancestral Indian practice aiming to connect the "body" and the "soul", the "self" and "the other". Traditionally, it is a philosophical way of living, sometimes combined with the practice of physical exercises. In westernized countries, Yoga is usually considered as a physical practice or an alternative therapy, using various techniques of breathing, relaxation and poses to release tensions and decrease pain.

Studies have already shown the effectiveness of yoga practice on various arthralgia's, on the reduction of inflammatory reactions, on psychological disorders/sleep disorders and on quality of life. Considering quality of life as a global experience of balance between physical and mental wellbeing, the hypothesis was that the practice of yoga, by improving these different aspects, would globally improve the quality of life of patients with chronic chikungunya.

Layout table for study information
Study Type : Interventional  (Clinical Trial)
Actual Enrollment : 42 participants
Allocation: Randomized
Intervention Model: Parallel Assignment
Intervention Model Description: randomized wait-list controlled design
Masking: Single (Outcomes Assessor)
Primary Purpose: Supportive Care
Official Title: Impact of Yoga on Quality of Life in Patients With Chronic Chikungunya: A Randomized Controlled Study
Actual Study Start Date : October 3, 2019
Actual Primary Completion Date : March 30, 2020
Actual Study Completion Date : March 30, 2020

Resource links provided by the National Library of Medicine

MedlinePlus related topics: Chikungunya

Arm Intervention/treatment
Experimental: Yoga
Yoga classes once a week for eight weeks
Other: Yoga group
During 8 weeks, the intervention group attended weekly yoga sessions and had to practice poses at home

Wait-list control
The delayed intervention group was to benefit from the intervention after week 8.
Other: Wait-list group
The wait-list group benefit from a 8-week yoga program after the interventional group




Primary Outcome Measures :
  1. Health Related Quality of Life - Short Form-36 (SF-36) [ Time Frame: At baseline ]
    This scale measures eight health domains (Physical Functioning, Role-Physical, Bodily Pain, General Health, Vitality, Social Functioning, Role-Emotional, Mental Health) of quality of life for adults aged 18 and older. Using a scoring algorithm, the aggregated scores can provide two summary scores: the physical component summary (PCS) score and the mental component summary (MCS) score.

  2. Health Related Quality of Life - Short Form-36 (SF-36) [ Time Frame: after 8 weeks of intervention ]
    This scale measures eight health domains (Physical Functioning, Role-Physical, Bodily Pain, General Health, Vitality, Social Functioning, Role-Emotional, Mental Health) of quality of life for adults aged 18 and older. Using a scoring algorithm, the aggregated scores can provide two summary scores: the physical component summary (PCS) score and the mental component summary (MCS) score.

  3. Health Related Quality of Life - Short Form-36 (SF-36) [ Time Frame: after 18 weeks ]
    This scale measures eight health domains (Physical Functioning, Role-Physical, Bodily Pain, General Health, Vitality, Social Functioning, Role-Emotional, Mental Health) of quality of life for adults aged 18 and older. Using a scoring algorithm, the aggregated scores can provide two summary scores: the physical component summary (PCS) score and the mental component summary (MCS) score.


Secondary Outcome Measures :
  1. nociceptive pain - Visual Analog Scale (VAS) [ Time Frame: At baseline ]
    The Visual Analog Scale (VAS) is a 10 cm line with anchor statements on the left (no pain) and on the right (extreme pain). The patient is asked to mark their current pain level on the line. They can also be asked to mark their maximum, minimum, and average pain. The examiner scores the VAS by measuring the distance in either centimeters (0 to 10) or millimeters (0 to 100) from the "no pain" anchor point.

  2. nociceptive pain - Visual Analog Scale (VAS) [ Time Frame: after 8 weeks of intervention ]
    The Visual Analog Scale (VAS) is a 10 cm line with anchor statements on the left (no pain) and on the right (extreme pain). The patient is asked to mark their current pain level on the line. They can also be asked to mark their maximum, minimum, and average pain. The examiner scores the VAS by measuring the distance in either centimeters (0 to 10) or millimeters (0 to 100) from the "no pain" anchor point.

  3. nociceptive pain - Visual Analog Scale (VAS) [ Time Frame: after 18 weeks ]
    The Visual Analog Scale (VAS) is a 10 cm line with anchor statements on the left (no pain) and on the right (extreme pain). The patient is asked to mark their current pain level on the line. They can also be asked to mark their maximum, minimum, and average pain. The examiner scores the VAS by measuring the distance in either centimeters (0 to 10) or millimeters (0 to 100) from the "no pain" anchor point.

  4. neuropathic pain- DN4 scale [ Time Frame: At baseline ]
    The total score is calculated as the sum of the 10 items and the cut-off value for the diagnosis of neuropathic pain is a total score of 4/10.

  5. neuropathic pain- DN4 scale [ Time Frame: after 8 weeks of intervention ]
    The total score is calculated as the sum of the 10 items and the cut-off value for the diagnosis of neuropathic pain is a total score of 4/10.

  6. neuropathic pain- DN4 scale [ Time Frame: after 18 weeks ]
    The total score is calculated as the sum of the 10 items and the cut-off value for the diagnosis of neuropathic pain is a total score of 4/10.



Information from the National Library of Medicine

Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the contacts provided below. For general information, Learn About Clinical Studies.


Layout table for eligibility information
Ages Eligible for Study:   18 Years to 70 Years   (Adult, Older Adult)
Sexes Eligible for Study:   All
Accepts Healthy Volunteers:   No
Criteria

Inclusion Criteria:

  • Patients suffering from chronic chikungunya, as documented by a positive chikungunya serology and the following symptoms: polyarthralgia and/or musculoskeletal disorder and/or morning stiffness.
  • Patients had to be between 18 and 70 years old, and be
  • patients affiliated to the French social insurance.

Exclusion Criteria:

  • being pregnant;
  • suffering from pre-existing rheumatic diseases before the Chikungunya infection;
  • showing acute symptoms of a Chikungunya infection (documented serology);
  • being unable to practice yoga poses ; having been recently treated with methotrexate or corticosteroids (less than 3 months ago);
  • being under guardianship, trusteeship or legal protection,
  • participating in another research study,
  • showing severely impaired physical and/or psychological health, which in the opinion of the investigator, may affect the compliance of the study participant.

Information from the National Library of Medicine

To learn more about this study, you or your doctor may contact the study research staff using the contact information provided by the sponsor.

Please refer to this study by its ClinicalTrials.gov identifier (NCT number): NCT04455919


Locations
Layout table for location information
Guadeloupe
Mouffias' Medical Center in Guadeloupe.
Pointe-à-Pitre, Guadeloupe, 97159
Sponsors and Collaborators
Centre Hospitalier Universitaire de Pointe-a-Pitre
Layout table for additonal information
Responsible Party: Centre Hospitalier Universitaire de Pointe-a-Pitre
ClinicalTrials.gov Identifier: NCT04455919    
Other Study ID Numbers: PAP/RI2/2019_05
2019-A01632-55 ( Other Identifier: ANSM )
First Posted: July 2, 2020    Key Record Dates
Last Update Posted: July 2, 2020
Last Verified: July 2020
Individual Participant Data (IPD) Sharing Statement:
Plan to Share IPD: No

Layout table for additional information
Studies a U.S. FDA-regulated Drug Product: No
Studies a U.S. FDA-regulated Device Product: No
Keywords provided by Centre Hospitalier Universitaire de Pointe-a-Pitre:
chikungunya virus
yoga
chronic chikungunya
Additional relevant MeSH terms:
Layout table for MeSH terms
Chikungunya Fever
Virus Diseases
Alphavirus Infections
Togaviridae Infections
RNA Virus Infections